- $304.51m
- $478.50m
- $114.20m
Agenus Inc expected to post a loss of 21 cents a share - Earnings Preview
Agenus rises on FDA's 'fast-track' tag for cancer therapy
Agenus rises on FDA's 'fast-track' tag for cancer therapy
Brief: Agenus Receives Fast Track Designation For Botensilimab And Balstilimab In Colorectal Cancer
Brief: Gain Therapeutics Appoints C. Evan Ballantyne As Chief Financial Officer
Brief: Agenus' Botensilimab In Combination With Balstilimab Shows 33% Durable Responses In Ovarian Cancer
Agenus Inc reports results for the quarter ended in December - Earnings Summary
Brief: Agenus Inc Reports Quarterly Loss Per Share Of $0.24
Brief: Agenus Says Has Cancelled Conference Call To Discuss Co's Minority Cash Holdings At Svb
Brief: Agenus Schedules Conference Call To Discuss Company's Minority Cash Holdings At SVB
Agenus Inc expected to post a loss of 22 cents a share - Earnings Preview
Agenus Inc expected to post a loss of 21 cents a share - Earnings Preview
Brief: Agenus Presents Clinical Data Demonstrating Durable Responses Of Botensilimab/Balstilimab Combination In Metastatic Microsatellite Stable Colorectal Cancer At ASCO GI
Brief: Agenus Inc Files For Common Stock Offering Of Up To 1.95 Million Shares By Selling Stockholders- SEC Filing
Brief: Agenus Data At CTOS 2022 Highlight Durable Clinical Responses Of Botensilimab / Balstilimab Combination In Advanced Sarcoma
Agenus Inc reports results for the quarter ended in September - Earnings Summary
Brief: Agenus Provides Corporate Update, Q3 Financial Report
Agenus Inc expected to post a loss of 19 cents a share - Earnings Preview
Brief: Agenus To Provide Corporate Update And Third Quarter 2022 Financial Report